Showing 721 - 740 results of 761 for search '"placebo"', query time: 0.06s Refine Results
  1. 721

    The Role of Omega-3 Polyunsaturated Fatty Acids in Patients with Metabolic Syndrome and Endothelial Dysfunction by Andrej Dzupina, Dominik Pella, Pavol Zenuch, Zuzana Zenuchova, Jaipaul Singh, Monika Jankajova, Jan Fedacko

    Published 2024-12-01
    “…The study evaluated endothelial function (EF) in subjects before and after a three-month treatment with n-3 PUFAs in a dose of 2.4 g daily (800 mg, three times a day) vs. placebo, using an Endo-PAT2000 device (Itamar Medical Ltd., Caesarea, Israel) measuring the reactive hyperemia index (a parameter of EF) and augmentation index (a parameter of arterial stiffness). …”
    Get full text
    Article
  2. 722
  3. 723

    Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyse... by Xiaodan Zhang, Lu Xing, Xiaona Jia, Xiaocong Pang, Qian Xiang, Xia Zhao, Lingyue Ma, Zhiyan Liu, Kun Hu, Zhe Wang, Yimin Cui

    Published 2020-01-01
    “…In this study, we searched four electronic databases for randomized controlled trials (RCTs) published through February 25, 2020, comparing the lipid-lowering efficacy of no less than two of the included statins (or statin vs. placebo). Three reviewers independently extracted data in duplicate. …”
    Get full text
    Article
  4. 724
  5. 725

    Caffeinated chewing gum enhances maximal strength and muscular endurance during bench press and back squat exercises in resistance-trained men by Li Ding, Jue Liu, Yi Yao, Li Guo, Bin Chen, Yinhang Cao, Olivier Girard

    Published 2025-01-01
    “…The aim of this study was to determine the efficacy of caffeinated chewing gum on maximal strength and muscular endurance during bench press and back squat exercises.MethodsIn a randomized, double-blind design, 16 resistance-trained males (age: 21.6 ± 2.0 years, height: 176.8 ± 6.1 cm, mass: 79.6 ± 8.8 kg) chewed either caffeinated gum (3 mg/kg) or a placebo gum on two occasions, 1 week apart. After a standardized warm-up, participants chewed the gum for 5 min before performing maximal strength test (one-repetition maximum [1RM]) and muscular endurance test (60% 1RM repetitions to failure) for bench press and back squat exercises. 1RM, number of repetitions, ratings of perceived exertion and pain perception were assessed.ResultsCaffeinated chewing gum significantly improved 1RM in both bench press (105.3 ± 14.5 vs. 100.3 ± 13.4 kg, +5.0% [95% confidence interval (CI): 3.7–6.3%], p < 0.01) and back squat (172.3 ± 20.2 vs. 161.9 ± 22.3 kg, +6.8% [95%CI: 4.1–9.5%], p < 0.01) exercises with small effect size (Cohen’s d: 0.36 [95%CI: 0.09–0.63] and 0.49 [95%CI: 0.22–0.76], respectively), despite similar levels of pain perception and RPE (p > 0.05). …”
    Get full text
    Article
  6. 726

    The effect of prednisolone ingestion and acute exercise on lipocalin-2 and its variants in young men: a pilot randomised crossover study by Carlie Bauer, Rhiannon K. Patten, Qiyang Sun, Haoyun Li, Daniels Konja, Mary Woessner, Xuzhu Lin, Andrew Garnham, David L. Hare, Peter R. Ebeling, Marc Sim, Joshua R. Lewis, Yu Wang, Lewan Parker, Itamar Levinger

    Published 2025-02-01
    “…In a randomised crossover design, nine young healthy men (aged 27.8 ± 4.9 years; BMI 24.4 ± 2.4 kg/m2) completed 30 min of high-intensity aerobic exercise (90–95% heart rate reserve) after glucocorticoid or placebo ingestion. Blood was collected and analyzed for LCN2 and its variants levels at baseline, immediately, 60 min and 180 min post-exercise. …”
    Get full text
    Article
  7. 727

    Effects of plant active substances in rheumatoid arthritis—a systematic review and network meta-analysis by Qiuwei Peng, Jian Wang, Kesong Li, Congming Xia, Chuanhui Yao, Qiuyan Guo, Xun Gong, Xiaopo Tang, Quan Jiang

    Published 2025-02-01
    “…Lastly, with respect to DAS28, resveratrol emerged as the optimal choice (74.3%).ConclusionAccording to the network meta-analysis (NMA), curcumin exhibited superior efficacy compared to placebo in decreasing SJC and TJC. Additionally, curcumin demonstrated greater effectiveness in reducing inflammatory markers. …”
    Get full text
    Article
  8. 728
  9. 729

    Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn’s Disease by Brian G. Feagan, Jean-Frederic Colombel, Remo Panaccione, Stefan Schreiber, Marc Ferrante, Koji Kamikozuru, Christopher Ma, Wan-Ju Lee, Jenny Griffith, Namita Joshi, Kristina Kligys, Jasmina Kalabic, Si Xuan, Marla Dubinsky

    Published 2025-01-01
    “…In contrast, patients who received placebo during maintenance had statistically similar rates of CD-related hospitalizations and surgeries regardless of achievement of endoscopic outcomes after induction. …”
    Get full text
    Article
  10. 730

    Multifunctional health-promoting effects of oolong tea and its products by Shuzhen Wang, Ting Zeng, Shuang Zhao, Yu Zhu, Changchun Feng, Jianfeng Zhan, Shiming Li, Chi-Tang Ho, Alexander Gosslau

    Published 2022-05-01
    “…However, potential health beneficial effects of oolong tea in humans should be further complemented by large-sized, randomized double-blind and placebo-controlled trials to consolidate potential therapeutic applications.…”
    Get full text
    Article
  11. 731

    Longitudinal impact of cross-clamp duration on postoperative sleep disturbance and quality of life in elderly cardiac surgery patients: a secondary analysis of the MINDDS trial by Grace E. Namirembe, Jamie Sparling, Alexis Novak, Ariel Mueller, Julia Bertsch, Kwame Wiredu, Jason Z. Qu, M. Brandon Westover, Timothy T. Houle, Oluwaseun Akeju

    Published 2025-01-01
    “…ObjectivesThis study aimed to assess the enduring impact of cross-clamp duration on postoperative sleep disturbance and functional outcomes (up to 180 days) in cardiac surgery patients.DesignThis is a secondary analysis of data from a randomized, double-blind trial comparing dexmedetomidine to placebo for delirium prevention (Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep).SettingData from patients recruited at a tertiary medical center in Boston, Massachusetts, between March 2017 and February 2022 were analyzed in January 2024.ParticipantsThe study included 394 patients aged ≥60 who underwent cardiac surgery with cardiopulmonary bypass.InterventionsThe primary exposure was cross-clamp time, while secondary exposures included surgical type [isolated coronary artery bypass graft (CABG) or not] and dexmedetomidine randomization.Measurements and main resultsThe primary outcome was sleep quality, assessed using the PROMIS Sleep Disturbance questionnaire at 30, 90, and 180 days postoperatively. …”
    Get full text
    Article
  12. 732

    Effects of non-pharmacological interventions on biochemical hyperandrogenism in women with polycystic ovary syndrome: a systematic review and network meta-analysis by Qi Jin, Ge Xu, Yuchen Ying, Lumin Liu, Huimin Zheng, Shifen Xu, Ping Yin, Yuelai Chen

    Published 2025-01-01
    “…Randomized controlled trials (RCTs) comparing NPIs with other NPIs or placebo treatments in adult women with PCOS were included. …”
    Get full text
    Article
  13. 733

    ImmunoglobuliN in the Treatment of Encephalitis (IgNiTE): protocol for a multicentre randomised controlled trial by R Kneen, M Lim, A Vincent, A J Pollard, W K Chong, L-M Yu, M A Iro, M Sadarangani, M Absoud, C A Clark, A Easton, V Gray, M Pike, T Solomon, L Willis

    Published 2016-11-01
    “…We describe the protocol for the first ever randomised control trial of IVIG treatment for children with all-cause encephalitis.Methods and analysis 308 children (6 months to 16 years) with a diagnosis of acute/subacute encephalitis will be recruited in ∼30 UK hospitals and randomised to receive 2 doses (1 g/kg/dose) of either IVIG or matching placebo, in addition to standard treatment. Recruitment will be over a 42-month period and follow-up of each participant will be for 12 months post randomisation. …”
    Get full text
    Article
  14. 734

    Investigating the impact of microbiome-changing interventions on food decision-making: MIFOOD study protocol by Meghedi Vartanian, Konrad Jakob Endres, Yee Teng Lee, Silke Friedrich, Marie-Theres Meemken, Imke Schamarek, Kerstin Rohde-Zimmermann, Robin Schürfeld, Lina Eisenberg, Anja Hilbert, Frauke Beyer, Michael Stumvoll, Julia Sacher, Arno Villringer, Julia F. Christensen, A. Veronica Witte

    Published 2025-01-01
    “…The interventions comprise either a daily supplementary intake of 30 g soluble fiber (inulin), or weekly neurocognitive behavioral group sessions, compared to placebo (equicaloric maltodextrin). At baseline and follow-up, food decision-making is assessed utilizing task-based MRI. …”
    Get full text
    Article
  15. 735

    The Use of L-Menthol in Endoscopic Transpapillary Interventions. Prospective Randomized Dual-Center Study by M. A. Anishchenko, M. A. Nazmeev, S. G. Shapovalyants, S. A. Budzinsky, A. V. Rogov, R. R. Zaynutdinov, A. S. Melnikova, E. D. Fedorov, E. N. Platonova

    Published 2023-12-01
    “…A prospective two-center randomized placebo-controlled trial was carried out from January to November 2022 in two centers. …”
    Get full text
    Article
  16. 736

    The effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild-to-moderate hypercholesterolemia: A confirmatory triple-blind randomized-controlled clinical t... by Mahdi Badiee Gavarti, Ali Askari, Hamidreza Roohafza, Mozhde Askari, Zahra Teimouri Jervekani, Shima Kaveh, Mohammad Kermanialghoraishi, Alireza Sadeghimahoonak, Masoumeh Sadeghi

    Published 2025-02-01
    “…Sixty patients were randomized with a 1:1 allocation ratio into the FHP group (N = 30) and the placebo group (N = 30). The intervention group was administrated 40 mg/day of FHP for 8 weeks. …”
    Get full text
    Article
  17. 737

    Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis by Andrew Thamboo, S. Kilty, I. Witterick, Y. Chan, C. J. Chin, A. Janjua, A. Javer, J. Lee, E. Monterio, B. Rotenberg, J. Scott, K. Smith, D. D. Sommer, L. Sowerby, M. Tewfik, E. Wright, M. Desrosiers

    Published 2021-03-01
    “…There have been eight randomized, double-blind, placebo-controlled trails performed for CRSwNP targeted components of the Type 2 inflammatory pathway, notably interleukin (IL)-4, IL-5 and IL-13, IL-5R, IL-33, and immunoglobulin (Ig)E. …”
    Get full text
    Article
  18. 738
  19. 739

    Interventions for the management of post-COVID-19 condition (long COVID): protocol for a living systematic review and network meta-analysis by Paul Garner, Lawrence Mbuagbaw, Jason W Busse, Dena Zeraatkar, Thomas Agoritsas, Ariel Izcovich, Tari Turner, Lyn Turkstra, Roger S McIntyre, Rachel J Couban, Tyler Pitre, Sarah Kirsh, Tanvir Jassal, Michael Ling, Samantha Chakraborty, Signe A Flottorp

    Published 2025-02-01
    “…Trustworthy systematic reviews that clarify the benefits and harms of interventions are critical to promote evidence-based practice.Objective To create and maintain a living systematic review and network meta-analysis addressing the benefits and harms of pharmacologic and non-pharmacologic interventions for the treatment and management of long COVID.Methods Eligible trials will randomise adults with long COVID to pharmacologic or non-pharmacologic interventions, placebo, sham or usual care. We will identify eligible studies by searching MEDLINE, EMBASE, CINAHL, PsycINFO, AMED and CENTRAL from inception, without language restrictions.Reviewers will work independently and in duplicate to screen search records, collect data from eligible trials, including trial and patient characteristics and outcomes of interest and assess risk of bias. …”
    Get full text
    Article
  20. 740

    Effect of nonsteroidal anti-inflammatory drugs on neonatal calf diarrhea when administered at a disease alert generated by automated milk feeders by A. Welk, M.C. Cantor, H.W. Neave, J.H.C. Costa, J.L. Morrison, C.B. Winder, D.L. Renaud

    Published 2025-02-01
    “…At their first alert, calves were randomly allocated to receive a single subcutaneous injection of meloxicam (Metacam, Boehringer Ingelheim) at a rate of 0.5 mg/kg of BW (NSAID) or an equal volume of saline as a placebo control (CON). Fecal consistency was scored daily, and calves were diagnosed with diarrhea when they had loose feces for ≥2 d or watery feces for ≥1 d. …”
    Get full text
    Article